Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 10, 2010 - Issue 12
Submit an article Journal homepage
497
Views
31
CrossRef citations to date
0
Altmetric
Drug Evaluation

The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis

Joost Frans Swart VU University Medical Center, Department of Pediatric Infectious diseases, Immunology and Rheumatology, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands +31 20 4444444; +31 20 4440844; [email protected]; UMC Utrecht, location Wilhelmina Children's Hospital, Department of Pediatric Immunology, Utrecht, The Netherlands; Reade, Centre for Revalidation and Rheumatology, Department of Rheumatology, Amsterdam, The Netherlands
, MD,
Daantje Barug VU University Medical Center, Department of Pediatric Infectious diseases, Immunology and Rheumatology, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands +31 20 4444444; +31 20 4440844; [email protected]
,
Michelle Möhlmann VU University Medical Center, Department of Pediatric Infectious diseases, Immunology and Rheumatology, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands +31 20 4444444; +31 20 4440844; [email protected]
&
Nico M Wulffraat UMC Utrecht, location Wilhelmina Children's Hospital, Department of Pediatric Immunology, Utrecht, The Netherlands
, MD PhD
Pages 1743-1752 | Published online: 28 Oct 2010

Citations (31)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Uwe Wollina. (2017) Emerging treatments for pyoderma gangrenosum. Expert Opinion on Orphan Drugs 5:10, pages 827-832.
Read now
Yvan Jamilloux, Mathieu Gerfaud-Valentin, Thomas Henry & Pascal Sève. (2015) Treatment of adult-onset Still’s disease: a review. Therapeutics and Clinical Risk Management 11, pages 33-43.
Read now
Sebastiaan J Vastert, Joost F Swart & Nico M Wulffraat. (2014) Evaluation of anakinra for the treatment of systemic juvenile idiopathic arthritis. Expert Opinion on Orphan Drugs 2:2, pages 181-188.
Read now
Nico M Wulffraat & Patricia Woo. (2013) Canakinumab in pediatric rheumatic diseases . Expert Opinion on Biological Therapy 13:4, pages 615-622.
Read now

Articles from other publishers (27)

Joseph R. Berger, Clyde Markowitz, Peter A. Merkel, Rachel A. Kolster & Zissimos Mourelatos. (2021) Multifocal neutrophilic meningoencephalitis: a novel disorder responsive to anakinra. Journal of Neurology 268:8, pages 2995-2999.
Crossref
Emma Rey-Jurado & María Cecilia Poli. (2021) Functional genetics in inborn errors of immunity. Future Rare Diseases 1:2.
Crossref
Charles F. SchulerIVIV, Carrie‐Anne Malinczak, Shannon K. K. Best, Susan B. Morris, Andrew J. Rasky, Catherine Ptaschinski, Nicholas W. Lukacs & Wendy Fonseca. (2020) Inhibition of uric acid or IL‐1β ameliorates respiratory syncytial virus immunopathology and development of asthma. Allergy 75:9, pages 2279-2293.
Crossref
Manel Mejbri, Katerina Theodoropoulou, Michael Hofer & Rolando Cimaz. (2020) Interleukin-1 Blockade in Systemic Juvenile Idiopathic Arthritis. Pediatric Drugs 22:3, pages 251-262.
Crossref
Benedetta Saccomanno, Jessica Tibaldi, Francesca Minoia, Francesca Bagnasco, Angela Pistorio, Andressa Guariento, Roberta Caorsi, Alessandro Consolaro, Marco Gattorno & Angelo Ravelli. (2019) Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis. The Journal of Rheumatology 46:4, pages 416-421.
Crossref
Petros Efthimiou & Sujani Yadlapati. 2019. Auto-Inflammatory Syndromes. Auto-Inflammatory Syndromes 261 276 .
Katherine A. Lyseng-Williamson. (2018) Anakinra in Still’s disease: a profile of its use. Drugs & Therapy Perspectives 34:12, pages 543-553.
Crossref
Baris Afsar, Adrian Covic, Alberto Ortiz, Rengin Elsurer Afsar & Mehmet Kanbay. (2018) The Future of IL-1 Targeting in Kidney Disease. Drugs 78:11, pages 1073-1083.
Crossref
Alessandro Consolaro & Nicola Ruperto. 2017. Pediatric Rheumatology. Pediatric Rheumatology 77 87 .
Gabriella Giancane, Francesca Minoia, Sergio Davì, Giulia Bracciolini, Alessandro Consolaro & Angelo Ravelli. (2016) IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis. Frontiers in Pharmacology 7.
Crossref
Brian A. BaldoBrian A. Baldo. 2016. Safety of Biologics Therapy. Safety of Biologics Therapy 217 261 .
Shweta Pasi, Ravi Kant, Sarika Gupta & Avadhesha Surolia. (2015) Novel multimeric IL-1 receptor antagonist for the treatment of rheumatoid arthritis. Biomaterials 42, pages 121-133.
Crossref
Brian A. Baldo. (2014) Side Effects of Cytokines Approved for Therapy. Drug Safety 37:11, pages 921-943.
Crossref
Frank R. Brennan. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies 969 1078 .
Sebastiaan J. Vastert, Wilco de Jager, Bo Jan Noordman, Dirk Holzinger, Wietse Kuis, Berent J. Prakken & Nico M. Wulffraat. (2014) Effectiveness of First-Line Treatment With Recombinant Interleukin-1 Receptor Antagonist in Steroid-Naive Patients With New-Onset Systemic Juvenile Idiopathic Arthritis: Results of a Prospective Cohort Study. Arthritis & Rheumatology 66:4, pages 1034-1043.
Crossref
Charles A. Dinarello & Jos W.M. van der Meer. (2013) Treating inflammation by blocking interleukin-1 in humans. Seminars in Immunology 25:6, pages 469-484.
Crossref
Marieke H Otten, Janneke Anink, Sandra Spronk & Lisette W A van Suijlekom-Smit. (2013) Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. Annals of the Rheumatic Diseases 72:11, pages 1806-1812.
Crossref
Sarah Ringold, Pamela F. Weiss, Timothy Beukelman, Esi Morgan DeWitt, Norman T. Ilowite, Yukiko Kimura, Ronald M. Laxer, Daniel J. Lovell, Peter A. Nigrovic, Angela Byun Robinson & Richard K. Vehe. (2013) 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among C. Arthritis & Rheumatism 65:10, pages 2499-2512.
Crossref
Sarah Ringold, Pamela F. Weiss, Timothy Beukelman, Esi Morgan DeWitt, Norman T. Ilowite, Yukiko Kimura, Ronald M. Laxer, Daniel J. Lovell, Peter A. Nigrovic, Angela Byun Robinson & Richard K. Vehe. (2013) 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among C. Arthritis Care & Research 65:10, pages 1551-1563.
Crossref
Femke H. M. Prince & Lisette W. A. van Suijlekom-Smit. (2013) Cost of Biologics in the Treatment of Juvenile Idiopathic Arthritis: A Factor not to be Overlooked. Pediatric Drugs 15:4, pages 271-280.
Crossref
Jeremy J. Edmunds. 2013. Drug Discovery. Drug Discovery 337 388 .
Joost F Swart, Sytze de Roock & Nico M Wulffraat. (2013) What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?. Arthritis Research & Therapy 15:3, pages 213.
Crossref
Hu-Yuan Tsai, Jyh-Hong Lee, Hsin-Hui Yu, Li-Chieh Wang, Yao-Hsu Yang & Bor-Luen Chiang. (2012) Initial manifestations and clinical course of systemic onset juvenile idiopathic arthritis: A ten-year retrospective study. Journal of the Formosan Medical Association 111:10, pages 542-549.
Crossref
Charles A. Dinarello, Anna Simon & Jos W. M. van der Meer. (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nature Reviews Drug Discovery 11:8, pages 633-652.
Crossref
D. Spoerl & Andreas J. Bircher. 2012. A worldwide yearly survey of new data in adverse drug reactions and interactions. A worldwide yearly survey of new data in adverse drug reactions and interactions 579 607 .
Robert S. Woodrick & Eric M. Ruderman. (2011) Safety of biologic therapy in rheumatoid arthritis. Nature Reviews Rheumatology 7:11, pages 639-652.
Crossref
NICO M. WULFFRAAT. (2011) Defining Criteria for Macrophage Activation Syndrome, a Process Towards Early Recognition and Treatment. The Journal of Rheumatology 38:4, pages 593-594.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.